EC
Erez Chimovits
Director

Erez Chimovits insider trades: ADARx Pharmaceuticals (ADRX) stock buys and sales

Director, ADARx Pharmaceuticals Last trade Sep 28, 2026 25 Form 4 filings
$0
Sold, last 12 months
0 sales
$36.0M
Bought, last 12 months
2 buys
12
Open-market trades
since 2018
7
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Erez reports to the SEC

and 1 more company

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 28, 2026ADRX↑ Buy$1.0M
Aug 7, 2026BRVE↑ Buy$34.9M
Oct 15, 2024UPB↑ Buy$14.0M
May 15, 2024PHGE↓ Sell$9K
Jun 27, 2023ACET↑ Buy$1.8M
Feb 27, 2023PHGE↑ Buy$85K
Oct 1, 2020LOGC↑ Buy$8.9M
Dec 19, 2019PHGE↑ Buy$36K
Dec 11, 2019PHGE↑ Buy$78K
Dec 9, 2019PHGE↑ Buy$86K
May 2, 2019NVUS↑ Buy$2.0M
Oct 23, 2018LOGC↑ Buy$4.9M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ADRX insiders

Open-market trades in the last 12 months

About Erez Chimovits's insider trades

Erez Chimovits is a director at ADARx Pharmaceuticals (ADRX). Since Oct 23, 2018, Erez has reported 11 open-market purchases worth $67.9M and 1 sale worth $9K on SEC Form 4. In the last 12 months: 2 buys ($36.0M).

Their filings also include grants and awards (11 filings), conversions (4 filings), other transactions (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ADRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.